Cover Image
市場調查報告書

全球焦慮症市場

Global Anxiety Disorders Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 323015
出版日期 內容資訊 英文 73 Pages
訂單完成後即時交付
價格
Back to Top
全球焦慮症市場 Global Anxiety Disorders Market 2015-2019
出版日期: 2015年01月14日 內容資訊: 英文 73 Pages
簡介

全球焦慮症市場,2014年達到了52億8000萬美元的規模。在各地區中,北美為53.54%有最大的市場佔有率,接著依序是歐洲、中東、非洲(EMEA)地區。可是,成長方率面,今後預計亞太地區迅速擴大。全球焦慮症市場,從2014年到2019年之間,預計以4.02%的年複合成長率擴大。

本報告提供全球焦慮症市場規模與其預測、成長要素和課題、主要供應商等資訊。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 焦慮症的種類

第7章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 各類藥物的市場區隔

第9章 地理區分

第10章 購買標準

第11章 市場成長因素

第12章 成長因素與其影響

第13章 市場課題

第14章 成長因素與課題的影響

第15章 市場趨勢

第16章 趨勢與其影響

第17章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
    • Eli Lilly
    • Pfizer
    • GlaxoSmithKline
  • 其他卓越供應商

第18章 主要供應商分析

  • Eli Lilly
  • GlaxoSmithKline
  • Pfizer

第19章 相關報告

目錄
Product Code: IRTNTR5051

About Anxiety Disorders

Anxiety is associated with uneasiness, fearfulness, and tension. Mild anxiety, for example, associated with exams or interview, is normal and triggers 'fight or flight' response. Anxiety without an identifiable cause, anxiety which persists even after the stressful condition is over, and anxiety which is out of proportion of the stressful condition indicates abnormal anxiety. However, severe and persistent anxiety can interfere with everyday activities and might lead to other psychic problems. Anxiety disorder is a mental health disorder characterized by the presence of anxiety. These disorders might occur simultaneously with other disorders such as depression, or along with drug abuse.

TechNavio's analysts forecast the Global Anxiety Disorders market to grow at a CAGR of 4.02 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Anxiety Disorders market for the period 2015-2019. To calculate the market size, the report considers the revenue generated through the sales of drugs approved for the treatment of the following anxiety disorders:

  • GAD
  • Panic Disorder
  • OCD
  • PTSD
  • Social Anxiety Disorder
  • Special Phobias
  • BDD

The report presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Anxiety Disorders market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, Global Anxiety Disorders Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Anxiety Disorders market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Eli Lilly and Company
  • GlaxoSmithKline
  • Pfizer

Other Prominent Vendors

  • Abbott Laboratories
  • Actavis
  • Baxter International
  • F. Hoffmann-La Roche
  • Noven Pharmaceuticals
  • Recordati Rare Diseases
  • Shionogi
  • Sumitomo Dainippon Pharma

Market Driver

  • Increase in Patient Population
  • For a full, detailed list, view our report

Market Challenge

  • Poor Diagnoses Rates
  • For a full, detailed list, view our report

Market Trend

  • Increased Focus on Emerging Markets
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Types of anxiety disorders

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Market Segmentation by Drug Class

09. Geographical Segmentation

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
    • 17.1.2. Mergers and Acquisitions
  • 17.2. Market Share Analysis 2014
    • 17.2.1. Eli Lilly
    • 17.2.2. Pfizer
    • 17.2.3. GlaxoSmithKline
  • 17.3. Other Prominent Vendors

18. Key Vendor Analysis

  • 18.1. Eli Lilly
    • 18.1.1. Key Facts
    • 18.1.2. Business Overview
    • 18.1.3. Business Segmentation by Revenue
    • 18.1.4. Sales by Geography
    • 18.1.5. Business Strategy
    • 18.1.6. Key Information
    • 18.1.7. SWOT Analysis
  • 18.2. GlaxoSmithKline
    • 18.2.1. Key Facts
    • 18.2.2. Business Overview
    • 18.2.3. Business Segmentation
    • 18.2.4. Business Segmentation by Revenue 2012 and 2013
    • 18.2.5. Sales by Geography
    • 18.2.6. Pipeline Products
    • 18.2.7. Business Strategy
    • 18.2.8. Key Information
    • 18.2.9. SWOT Analysis
  • 18.3. Pfizer
    • 18.3.1. Key Facts
    • 18.3.2. Business Overview
    • 18.3.3. Business Segmentation by Revenue 2013
    • 18.3.4. Business Segmentation by Revenue 2012 and 2013
    • 18.3.5. Geographical Segmentation by Revenue
    • 18.3.6. Business Strategy
    • 18.3.7. Key Developments
    • 18.3.8. SWOT Analysis

19. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Classification of Anxiety Disorders
  • Exhibit 3: GAD: Disease Overview
  • Exhibit 4: Panic Disorder: Disease Overview
  • Exhibit 5: OCD: Disease Overview
  • Exhibit 6: PTSD: Disease Overview
  • Exhibit 7: Social Anxiety Disorder: Disease Overview
  • Exhibit 8: Specific Phobias: Disease Overview
  • Exhibit 9: BDD: Disease Overview
  • Exhibit 10: Global Anxiety Disorders Market 2014-2019 (US$ billion)
  • Exhibit 11: Global Anxiety Disorders Market Segmentation by Drug Class
  • Exhibit 12: Segmentation of Global Anxiety Disorders Market by Geography 2014
  • Exhibit 13: Cymbalta: Basic Information
  • Exhibit 14: Cymbalta Revenue 2011-9M 2014 (US$ million)
  • Exhibit 15: Revenue Segmentation by Geography 9M 2014
  • Exhibit 16: Pfizer: Revenue of Key Anti-Anxiety Products 9M 2014 (US$ million)
  • Exhibit 17: Lyrica: Basic Information
  • Exhibit 18: Lyrica Revenue 2011-9M 2014 (US$ million)
  • Exhibit 19: Revenue Segmentation by Geography 9M 2014
  • Exhibit 20: Zoloft: Basic Information
  • Exhibit 21: Zoloft Revenue 2011-9M 2014 (US$ million)
  • Exhibit 22: Revenue Segmentation by Geography 9M 2014
  • Exhibit 23: Effexor and Effexor XR: Basic Information
  • Exhibit 24: Effexor/Effexor XR Revenue 2011-9M 2014 (US$ million)
  • Exhibit 25: Revenue Segmentation by Geography 9M 2014
  • Exhibit 26: Xanax and Xanax XR: Basic Information
  • Exhibit 27: Xanax/Xanax XR Revenue 2011-9M 2014 (US$ million)
  • Exhibit 28: Revenue Segmentation by Geography 9M 2014
  • Exhibit 29: Seroxat/Paxil/Paxil CR: Basic Information
  • Exhibit 30: Seroxat/Paxil Revenue 2011-9M 2014 (US$ million)
  • Exhibit 31: Revenue Segmentation by Geography 9M 2014
  • Exhibit 32: Eli Lilly: Business Segmentation by Revenue 2013
  • Exhibit 33: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 34: Eli Lilly: Sales by Geography 2013
  • Exhibit 35: GlaxoSmithKline plc: Business Segmentation 2013
  • Exhibit 36: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 37: GlaxoSmithKline plc: Sales by Geography 2013
  • Exhibit 38: GlaxoSmithKline plc: Pipeline Products 2013
  • Exhibit 39: Pfizer: Business Segmentation by Revenue 2013
  • Exhibit 40: Pfizer: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 41: Pfizer: Geographical Segmentation by Revenue 2013
Back to Top